Added value of randomized biopsy to mpMRI-targeted biopsy of the prostate in a contemporary cohort.

Michael ChaloupkaNikolaos PyrgidisBenedikt Ebner Yannic VolzPaulo L PfitzingerElena BergBenazir EnzingerMichael AtzlerTroya IvanovaDirk-André ClevertAlexander BuchnerChristian G StiefMaria Apfelbeck

Published in: BJU international (2023)

To assess the added value of concurrent systematic randomized ultrasound-guided biopsy (SBx) to multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy and the additional rate of overdiagnosis of clinically insignificant prostate cancer (ciPCa) by SBx in a large contemporary, real-world cohort.

Keyphrases

ultrasound guided
fine needle aspiration
prostate cancer
magnetic resonance imaging
double blind
open label
placebo controlled
phase iii
cancer therapy
radical prostatectomy
clinical trial
computed tomography
phase ii
randomized controlled trial
squamous cell carcinoma
drug delivery